Performance of the OraQuick rapid antibody test for diagnosis of human immunodeficiency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapy.
With oral mucosal transudate and serum samples from 101 human immunodeficiency virus type 1 (HIV-1)-infected subjects and 100 HIV-1-negative volunteers, the OraQuick HIV-1 test demonstrated 100% specificity and 96% sensitivity. Four false-negative subjects, who were characterized by early initiation of effective antiretroviral therapy, demonstrated waning serum anti-gp41 titers and Western blot band intensities.
Department of Infectious Diseases, Wilford Hall Medical Center, Lackland Air Force Base, Texas 78236, USA. robert.oconnell@lackland.af.mil
Robert J
RJ
O'Connell
Teresa M
TM
Merritt
Jennifer A
JA
Malia
Thomas C
TC
VanCott
Matthew J
MJ
Dolan
Hassan
H
Zahwa
William P
WP
Bradley
Bernard M
BM
Branson
Nelson L
NL
Michael
Caroline C
CC
De Witt
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D015153:Blotting, Western; D016022:Case-Control Studies; D005188:False Negative Reactions; D005260:Female; D015483:HIV Antibodies / Q000032:analysis* / Q000097:blood; D015700:HIV Envelope Protein gp41 / Q000276:immunology; D015658:HIV Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007118:Immunoassay / Q000379:methods* / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D009061:Mouth Mucosa / Q000276:immunology; D012680:Sensitivity and Specificity
D015483:HIV Antibodies; D015700:HIV Envelope Protein gp41